• Separating Growth Inhibition from Cancer Cell Killing

  2026-08-23

  Hannah Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is an assay-interpretation framework that separates proliferative arrest from cell death and accounts for differences in response magnitude and timing.

• AGO1, Protein Folding, and mESC Fate Decisions

  2026-08-22

  The 2024 Developmental Cell study identifies an RNA-independent function of AGO1 in mouse embryonic stem cells: through the co-chaperone HOP, AGO1 promotes folding of selected transcription factors and supports stemness. Its contrast with AGO2, which promotes differentiation through the microRNA pathway, broadens the mechanistic framework for embryonic stem cell pluripotency maintenance beyond canonical small-RNA silencing.

• 4-MUG: Fluorogenic Lysosomal Enzyme Assays

  2026-08-21

  4-Methylumbelliferyl-β-D-Glucopyranoside, also called 4-MUG, is a fluorogenic glycoside substrate for β-glucosidase and β-glucocerebrosidase activity assays. Its hydrolysis releases 4-methylumbelliferone, enabling fluorescence-based measurements that support lysosomal enzyme and Gaucher disease research.

• Plant Protein Secretion: Methods and Research Insights

  2026-08-21

  Plant Protein Secretion: Methods and Protocols, Second Edition, organizes current experimental approaches around the distinctive organization of plant secretory and endomembrane systems. Its main contribution is methodological: reproducible, stepwise workflows help researchers distinguish conventional and unconventional secretion while accounting for plant-specific compartments such as the trans-Golgi network and prevacuolar compartment.

• BRD4770: G9a Histone Methyltransferase Inhibitor

  2026-08-20

  BRD4770 is a practical small-molecule probe for connecting G9a activity with H3K9 methylation, senescence, and cancer-cell growth. This workflow emphasizes formulation control, orthogonal chromatin readouts, and a reference-informed strategy for extending studies from PANC-1 cells to broader tumor models.

• Ferroptosis Inducers in Advanced Prostate Cancer

  2026-08-20

  Ghoochani et al. show that treatment-resistant prostate cancer retains a therapeutically exploitable dependence on ferroptosis-regulating pathways. Their preclinical data position erastin and RSL3, alone or combined with second-generation anti-androgens, as strategies that suppress tumor-cell growth, migration, and tumor progression.

• RNA Pol II Inhibition and the PDAR Apoptotic Pathway

  2026-08-19

  Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic signaling program rather than through passive loss of transcription and mRNA decay. Their identification of the Pol II degradation-dependent apoptotic response (PDAR) reframes how transcription-targeting drugs may produce therapeutic cell death and provides a mechanistic framework for interpreting drug sensitivity.

• Y-27632: ROCK Inhibitor Workflow for Cancer Cells

  2026-08-18

  Y-27632 provides reversible ROCK1 and ROCK2 inhibition for controlled cytoskeletal dynamics modulation, stress-fiber imaging, migration assays, and organoid workflows. This guide connects practical ROCK perturbation with the TSPAN18–STIM1 mechanism reported in prostate cancer bone metastasis research while separating established evidence from assay-development recommendations.

• CX-5461 Induces Mitotic Catastrophe in Cervical Cancer

  2026-08-18

  The reference study identifies a mechanism by which the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth: DNA damage activates ATM/ATR signaling while abnormal Cyclin B1–CDK1 control forces damaged cells into mitosis and mitotic catastrophe. The work also shows that CX-5461 can increase cisplatin sensitivity, providing a mechanistic rationale for combination strategies in platinum-resistant disease.

• SkQ1, Ovarian Cancer, and Skeletal Muscle Atrophy

  2026-08-17

  The reference study uses a time-resolved orthotopic epithelial ovarian cancer model to test whether mitochondrial hydrogen peroxide, apoptotic caspases, and necroptotic signalling drive skeletal muscle atrophy. SkQ1 normalized late-stage mitochondrial oxidative and caspase signals without restoring fibre size, separating regulated cell-death signalling from the causal mechanisms of muscle loss.

• Amyloid β-Peptide (1-42) Workflow Guide

  2026-08-17

  Build reproducible Aβ42 peptide models that connect aggregation state with neuronal toxicity, microglial clearance, and ion-channel behavior. This practical workflow emphasizes DMSO handling, time-resolved ATP/P2Y2 assays, and controls that distinguish peptide biology from preparation artifacts.

• Phosbind Acrylamide: Practical SDS-PAGE Guide

  2026-08-16

  Phosbind Acrylamide (F4002) is a phosphate-binding reagent for detecting phosphorylation-dependent mobility shifts during SDS-PAGE without relying on phospho-specific antibodies. It is suited to proteins in the 30–130 kDa range, but it should not be treated as a phosphorylation-site mapping method or as standalone proof of protein identity.

• Laminin (925-933): From ECM Signal to Translation

  2026-08-15

  A translational framework for using Laminin (925-933), a defined Laminin B1 chain peptide, to interrogate receptor-dependent cell adhesion, migration, and chemotaxis while connecting extracellular matrix assay design with emerging neurodegeneration research.

• Triamcinolone (B1859): Practical Lab Guide

  2026-08-15

  Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide covers solvent selection, solid and solution handling, assay setup, and quality control; the compound is for scientific research only and is not intended for diagnostic or clinical use.

• SmD2 Acetylation Rewires PARP Sensitivity in HCC

  2026-08-14

  This 2024 Nature Communications study identifies SmD2 acetylation as a regulatory link between core spliceosome function, BRCA1/FANC cassette-exon selection, DNA repair, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its preclinical data support testing SmD2–HDAC2–p300 biology as a biomarker-guided strategy for PARP inhibitor combinations in BRCA-proficient HCC.

451 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page